Evidence map›Paper›PMID 42231151›Full record

ArticleCellular & molecular biology letters2026

Phosphoproteomic profiling reveals post-translational dysregulation in Huntington's disease patient-derived neurons.

Lea Danics, Chandramouli Muralidharan, Ágnes Varga, Melinda Rezeli, Jeovanis Gil, Anna A Abbas, Ádám Pap, Andrew S Park, Marcell Cserhalmi, Emilie M Legault and 9 more

Abstract read
In one paragraph

Article in Cellular & molecular biology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Lea Danics *Institute of Clinical Pathophysiology, Semmelweis University, Budapest, Hungary.
Chandramouli Muralidharan *Hungarian Centre of Excellence for Molecular Medicine-Semmelweis University (HCEMM-SU), Neurobiology and Neurodegenerative Diseases Research Group, Budapest, Hungary.
Ágnes VargaInstitute of Clinical Pathophysiology, Semmelweis University, Budapest, Hungary.
Melinda RezeliDivision for Biomedical Engineering, Department of Biomedical Engineering, Lund University, Lund, Sweden.
Jeovanis GilClinical Chemistry, Department of Translational Medicine, Lund University, Lund, Sweden.
Anna A AbbasInstitute of Clinical Pathophysiology, Semmelweis University, Budapest, Hungary.
Ádám PapSingle Cell Omics Advanced Core Facility, Hungarian Centre of Excellence for Molecular Medicine, Szeged, Hungary.
Andrew S ParkFaculty of Pharmacy, University of Montreal, Montreal, QC, Canada.
Marcell CserhalmiMTA-HUN-REN RCNS Lendület "Momentum" DNA Repair Research Group, Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary.
Emilie M LegaultFaculty of Pharmacy, University of Montreal, Montreal, QC, Canada.
Ármin SőthInstitute of Clinical Pathophysiology, Semmelweis University, Budapest, Hungary.
Dorina JamniczkyInstitute of Clinical Pathophysiology, Semmelweis University, Budapest, Hungary.
Roland ZsoldosInstitute of Clinical Pathophysiology, Semmelweis University, Budapest, Hungary.
Roger A BarkerCambridge Stem Cell Institute and John Van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Cambridge, UK.
Gergely RónaMTA-HUN-REN RCNS Lendület "Momentum" DNA Repair Research Group, Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary.
Janelle Drouin-OuelletFaculty of Pharmacy, University of Montreal, Montreal, QC, Canada.
György Markó-VargaBioMS-Swedish National Infrastructure for Biological Mass Spectrometry, Lund University, Lund, Sweden.
Zsuzsanna DarulaSingle Cell Omics Advanced Core Facility, Hungarian Centre of Excellence for Molecular Medicine, Szeged, Hungary.
Karolina PircsInstitute of Clinical Pathophysiology, Semmelweis University, Budapest, Hungary. pircs.karolina@semmelweis.hu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Huntington's disease (HD) is a fatal neurodegenerative disorder caused by a CAG repeat expansion in the Huntingtin gene. Although transcriptomic and proteomic changes have been characterized in patient-derived neurons, the contribution of post-translational modifications, such as phosphorylation, remains poorly understood. Here, we present the first phosphoproteomic analysis by mass spectrometry (P-MS) of human induced neurons (iNs) directly reprogrammed from HD patient fibroblasts. We identified 177 phosphopeptides with significantly altered abundance in HD-iNs, mapping to phosphoproteins associated with key signaling pathways known to be affected in HD, such as splicing and autophagy. By integrating P-MS data with previously published proteomic and transcriptomic data from the same donors, we identified distinct subsets of ON-OFF phosphopeptides that exhibited a complete loss of phosphorylation in either HD- or control-iNs, without corresponding changes at the RNA or protein level. An exception was MXRA8, previously described in glial cells as a mediator of blood-brain barrier integrity and astrocyte-mediated neuroinflammation. This protein showed increased protein abundance despite the absence of phosphorylation in HD-iNs, suggesting a compensatory mechanism. In addition, MXRA8 showed altered protein-protein interactions with lysosomal and metabolic regulators in HD-iNs, highlighting its potential role in autophagy impairment as well as in neurovascular dysfunction. These findings uncover a distinct layer of post-translational dysregulation in HD, suggesting that phospho-switch proteins such as MXRA8 may be candidate effectors of pathology, and thus, site-specific phosphorylation loss may contribute to impaired signaling and proteostasis in human HD neurons.

Indexed as

Huntington DiseaseNeuronsPhosphoproteinsProtein Processing, Post-TranslationalProteomicsAutophagyHumansPhosphorylationPhosphoproteinsAutophagyHuntington’s diseaseInduced neuronsMXRA8PhosphorylationPost-translational modification

Identifiers

PMID42231151
PMCPMC13445741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.